File: /home/govancoz/mail/.spam/new/1694949547.M406073P2272034.zacp120.ve.host,S=9973,W=10153
Return-Path: <marijke@publify.co.za>
Delivered-To: govancoz+spam@zacp120.ve.host
Received: from zacp120.ve.host
by zacp120.ve.host with LMTP
id QGqoFqvgBmUiqyIAvcbEzQ
(envelope-from <marijke@publify.co.za>)
for <govancoz+spam@zacp120.ve.host>; Sun, 17 Sep 2023 13:19:07 +0200
Return-path: <marijke@publify.co.za>
Envelope-to: cheryl@govan.co.za
Delivery-date: Sun, 17 Sep 2023 13:19:07 +0200
Received: from server.cal.wdi.mybluehost.me ([162.240.226.30]:46138)
by zacp120.ve.host with esmtps (TLS1.2) tls TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384
(Exim 4.96)
(envelope-from <marijke@publify.co.za>)
id 1qhpns-009XI6-0F
for cheryl@govan.co.za;
Sun, 17 Sep 2023 13:19:07 +0200
DKIM-Signature: v=1; a=rsa-sha256; q=dns/txt; c=relaxed/relaxed;
d=publify.co.za; s=default; h=Reply-To:Date:From:To:Subject:MIME-Version:
Content-Type:Sender:Message-ID:Cc:Content-Transfer-Encoding:Content-ID:
Content-Description:Resent-Date:Resent-From:Resent-Sender:Resent-To:Resent-Cc
:Resent-Message-ID:In-Reply-To:References:List-Id:List-Help:List-Unsubscribe:
List-Subscribe:List-Post:List-Owner:List-Archive;
bh=+89WZB8tmKI8+f9XiUeMCSVq/zGyzZnx5OxFb1aSHN8=; b=gn/OMLzPMtTS0QWWzE+dbYNe1O
l0Wq77HEcG9kKBCIUgTp+/zNfl2hhdn4FaadFa5KnvADlCd0FvFXNSQSGJaCJwsrxHgmiSzt1DpAh
f9DIwrLlZmIoucwOJJY6e2HZ62M+2nFseiaEG//wPzFWFkJf4U3OD1aHcENAV+NtEYVqHuCZ/mvkp
rpixJuZmru6CQWw9RIqzGlaKQETBZn33Id1FgqeI/38uj/UZEGW6m82H9YvujRTx31eodrfmcGFbg
RWH35gehZteStvrzvs6gtTjlhz7W3UGWb1Gd5GE51IErAzITBgzKqHPe1NAqA6m5i3/TWh7QCE4nd
2UMGbMcA==;
Received: from ns1001864.ip-92-204-128.us ([92.204.128.76]:22071 helo=[169.254.129.240])
by publify.cal.wdi.mybluehost.me with esmtpa (Exim 4.96)
(envelope-from <marijke@publify.co.za>)
id 1qgKAV-0008D9-23;
Wed, 13 Sep 2023 09:20:11 +0200
Content-Type: multipart/alternative; boundary="===============0408666944=="
MIME-Version: 1.0
To: Recipients <marijke@publify.co.za>
From: "Dr. Yasunobu Otsuga" <marijke@publify.co.za>
Date: Wed, 13 Sep 2023 00:19:44 -0700
Reply-To: yasunobuotsuga1@gmail.com
X-AntiAbuse: This header was added to track abuse, please include it with any abuse report
X-AntiAbuse: Primary Hostname - publify.cal.wdi.mybluehost.me
X-AntiAbuse: Original Domain - govan.co.za
X-AntiAbuse: Originator/Caller UID/GID - [47 12] / [47 12]
X-AntiAbuse: Sender Address Domain - publify.co.za
X-Get-Message-Sender-Via: publify.cal.wdi.mybluehost.me: authenticated_id: marijke@publify.co.za
X-Authenticated-Sender: publify.cal.wdi.mybluehost.me: marijke@publify.co.za
X-Source:
X-Source-Args:
X-Source-Dir:
X-Spam-Status: Yes, score=9.5
X-Spam-Score: 95
X-Spam-Bar: +++++++++
X-Spam-Report: Spam detection software, running on the system "zacp120.ve.host",
has identified this incoming email as possible spam. The original
message has been attached to this so you can view it or label
similar future email. If you have any questions, see
root\@localhost for details.
Content preview: Hello Daito Pharma Co., Ltd. is a Japan-based manufacturing
pharmaceutical company engaged in the pharmaceutical ingredients and formulation
business . Are you interested in working with us to be our [...]
Content analysis details: (9.5 points, 5.0 required)
pts rule name description
---- ---------------------- --------------------------------------------------
4.5 URIBL_DBL_SPAM Contains a spam URL listed in the Spamhaus DBL
blocklist
[URIs: publify.co.za]
0.5 SUBJ_ALL_CAPS Subject is all capitals
-0.0 SPF_PASS SPF: sender matches SPF record
0.2 FREEMAIL_REPLYTO_END_DIGIT Reply-To freemail username ends in
digit
[yasunobuotsuga1[at]gmail.com]
0.0 HTML_MESSAGE BODY: HTML included in message
-0.1 DKIM_VALID Message has at least one valid DKIM or DK signature
0.1 DKIM_SIGNED Message has a DKIM or DK signature, not necessarily
valid
-0.1 DKIM_VALID_EF Message has a valid DKIM or DK signature from
envelope-from domain
-0.1 DKIM_VALID_AU Message has a valid DKIM or DK signature from
author's domain
2.0 PYZOR_CHECK Listed in Pyzor
(https://pyzor.readthedocs.io/en/latest/)
0.0 FSL_BULK_SIG Bulk signature with no Unsubscribe
2.5 FREEMAIL_FORGED_REPLYTO Freemail in Reply-To, but not From
X-Spam-Flag: YES
Subject: ***SPAM*** WE ARE INTERESTED TO PARTNER WITH YOU.
You will not see this in a MIME-aware mail reader.
--===============0408666944==
Content-Type: text/plain; charset="utf-8"
MIME-Version: 1.0
Content-Transfer-Encoding: quoted-printable
Content-Description: Mail message body
Hello =
Daito Pharma Co., Ltd. is a Japan-based manufacturing pharmaceutical comp=
any engaged in the pharmaceutical ingredients and formulation business . Ar=
e you interested in working with us to be our company representative in you=
r country, The Republic of South Africa, for a period of five years contrac=
t? Please Kindly let us know if you are interested while I direct you to m=
y working company email address =
Apologies for using my personal email address for these proposals. However=
, The reason was to get an immediate notification from you once you respond=
ed. =
Best regards,
Dr. Yasunobu Otsuga President & CEO Daito Pharmaceutical Co., Ltd. 326 Yoka=
machi, Toyama City, Toyama Prefecture 939-8567
--===============0408666944==
Content-Type: text/html; charset="utf-8"
MIME-Version: 1.0
Content-Transfer-Encoding: quoted-printable
Content-Description: Mail message body
<HTML><head><meta http-equiv=3D"Content-Type" content=3D"text/html; charset=
=3Dutf-8"/></head><BODY><DIV style=3D"FONT-SIZE: small; FONT-FAMILY: Arial,=
Helvetica, sans-serif; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSF=
ORM: none; FONT-WEIGHT: 400; COLOR: rgb(34,34,34); FONT-STYLE: normal; ORPH=
ANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-l=
igatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px=
; text-decoration-thickness: initial; text-decoration-style: initial; text-=
decoration-color: initial">Hello</DIV>
<DIV style=3D"FONT-SIZE: small; FONT-FAMILY: Arial, Helvetica, sans-serif; =
WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: =
400; COLOR: rgb(34,34,34); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; LETTE=
R-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-v=
ariant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-thickn=
ess: initial; text-decoration-style: initial; text-decoration-color: initia=
l"><BR></DIV>
<DIV style=3D"FONT-SIZE: small; FONT-FAMILY: Arial, Helvetica, sans-serif; =
WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: =
400; COLOR: rgb(34,34,34); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; LETTE=
R-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-v=
ariant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-thickn=
ess: initial; text-decoration-style: initial; text-decoration-color: initia=
l">Daito Pharma Co., Ltd. is a Japan-based manufacturing pharmaceutic=
al company engaged in the pharmaceutical ingredients and formulation busine=
ss . Are you interested in working with us to be our company representative=
in your country, The Republic of South Africa, for a period of five years =
contract? Please Kindly let us know if you are interested while I dir=
ect you to my working company email address</DIV>
<DIV style=3D"FONT-SIZE: small; FONT-FAMILY: Arial, Helvetica, sans-serif; =
WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: =
400; COLOR: rgb(34,34,34); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; LETTE=
R-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-v=
ariant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-thickn=
ess: initial; text-decoration-style: initial; text-decoration-color: initia=
l">
<DIV><BR></DIV>
<DIV>Apologies for using my personal email address for these proposals. How=
ever, The reason was to get an immediate notification from you once you res=
ponded.</DIV></DIV>
<DIV style=3D"FONT-SIZE: small; FONT-FAMILY: Arial, Helvetica, sans-serif; =
WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: =
400; COLOR: rgb(34,34,34); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; LETTE=
R-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-v=
ariant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-thickn=
ess: initial; text-decoration-style: initial; text-decoration-color: initia=
l"><BR></DIV>
<DIV style=3D"FONT-SIZE: small; FONT-FAMILY: Arial, Helvetica, sans-serif; =
WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: =
400; COLOR: rgb(34,34,34); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; LETTE=
R-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-v=
ariant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-thickn=
ess: initial; text-decoration-style: initial; text-decoration-color: initia=
l">
<DIV><SPAN style=3D"FONT-SIZE: 11pt; FONT-FAMILY: Gulim, =EA=B5=B4=EB=A6=BC=
, sans-serif; COLOR: rgb(0,0,0)">Best regards,</SPAN><BR style=3D"FON=
T-SIZE: 14px; FONT-FAMILY: Gulim, =EA=B5=B4=EB=A6=BC, sans-serif; COLOR: rg=
b(0,0,0)"><SPAN style=3D"FONT-SIZE: 11pt"><SPAN style=3D"FONT-FAMILY: Gulim=
, =EA=B5=B4=EB=A6=BC, sans-serif; COLOR: rgb(0,0,0)">Dr. </SPAN></SPAN=
>Yasunobu Otsuga</DIV>
<DIV><SPAN style=3D"FONT-SIZE: 11pt; FONT-FAMILY: Gulim, =EA=B5=B4=EB=A6=BC=
, sans-serif; COLOR: rgb(0,0,0)">President & CEO</SPAN></DIV>
<DIV>Daito Pharmaceutical Co., Ltd.</DIV>
<DIV>326 Yokamachi, Toyama City, Toyama Prefecture 939-8567</DIV></DIV></BO=
DY></HTML>
--===============0408666944==--